MRC2 Antibody

What is MRC2 and what cell types typically express this protein?

MRC2 (Mannose Receptor C type 2) is a type I transmembrane glycoprotein belonging to the macrophage mannose receptor family. It is also known by several alternative names including CD280, Endo180, UPARAP, CLEC13E, C-type mannose receptor 2, and C-type lectin domain family 13 member E . The protein has a molecular weight of approximately 166.7-180 kDa and contains several domains including an N-terminal cysteine-rich domain, a fibronectin type II domain (FNII), eight C-type-lectin-like domains, and a transmembrane region followed by a small cytoplasmic domain .

MRC2 is primarily expressed in:

• Fibroblasts

• Endothelial cells

• Macrophages

• Some cancer cell lines (e.g., THP-1 cells, but not A431 cells)

For experimental validation, researchers should consider:

• Using appropriate positive and negative control cell types

• Confirming expression through multiple methods (WB, qPCR, immunostaining)

• Recognizing that expression levels may vary with developmental stage

What are the primary functions of MRC2 that make it a target of research interest?

MRC2 functions as a multifunctional receptor involved in several important biological processes:

• Collagen processing: Acts as an endocytic receptor for collagen uptake and intracellular degradation, contributing to extracellular matrix remodeling

• Cell adhesion and migration: Participates in mechanisms that promote cell movement through tissues

• Plasminogen activation: May be involved in regulating extracellular protease activity via the plasminogen activation system

• Endocytosis: Functions as a constitutively recycling receptor with rapid internalization (>50% internalized within 2 minutes)

These functions make MRC2 particularly relevant to research in:

• Tissue remodeling and fibrosis

• Cancer progression and metastasis

• Age-dependent collagen turnover

• Extracellular matrix homeostasis

What applications are MRC2 antibodies commonly used for?

Based on supplier information and literature references, MRC2 antibodies are validated for multiple applications:

When selecting an antibody for a specific application, researchers should review validation data for each product in their species and application of interest.

How should I select between monoclonal and polyclonal MRC2 antibodies for my research?

The choice between monoclonal and polyclonal antibodies depends on your experimental goals:

Monoclonal antibodies (e.g., MAB5770, Anti-MRC2/ENDO180 Rabbit Monoclonal) :

• Advantages: High specificity to a single epitope, consistent lot-to-lot reproducibility, reduced background

• Best for: Experiments requiring precise epitope targeting, flow cytometry, therapeutic applications

• Considerations: May be less robust to fixation or denaturation conditions that alter the specific epitope

Polyclonal antibodies (e.g., AF5770, MRC2 Rabbit Polyclonal) :

• Advantages: Recognize multiple epitopes, often more tolerant to protein denaturation, potentially higher sensitivity

• Best for: Western blotting, immunoprecipitation, detecting proteins at low expression levels

• Considerations: Potential for higher background, greater lot-to-lot variation

For critical experiments, consider:

• Validating with both types if possible

• Using monoclonals for quantitative comparisons between samples

• Using polyclonals for maximal detection in applications like western blotting

What are the optimal sample preparation methods for MRC2 detection in different applications?

For Western Blotting:

• Use RIPA buffer with protease inhibitors for cell/tissue lysis

• Centrifuge at 16,000 × g for 30 minutes at 4°C to clear debris

• Sonicate lysates to reduce viscosity

• Load 15-20 μg protein per lane

• Run under reducing conditions on 4-15% gradient gels

• Transfer to PVDF membranes for optimal results

For Immunofluorescence/Immunocytochemistry:

• For membrane staining: Use antibody diluted in binding buffer (DMEM with 10 mM HEPES pH 7.5, 2 mg/mL BSA)

• Fixation: 4% paraformaldehyde preserves MRC2 structure

• For intracellular detection: Permeabilize with 0.5% Triton X-100

• Use appropriate counterstains (e.g., DAPI for nuclei, phalloidin for actin)

For Flow Cytometry:

• Use freshly isolated cells or cultured cells in single-cell suspension

• Recommended antibody concentration: 0.25 μg per 10^6 cells

• Include proper isotype controls to assess background staining

What controls are essential when working with MRC2 antibodies?

Positive controls:

• Cell lines with confirmed MRC2 expression (e.g., THP-1, HEK293, MG-63)

• Tissue samples known to express MRC2 (e.g., lung, heart, kidney)

Negative controls:

• Cell lines lacking MRC2 expression (e.g., A431 cells)

• MRC2 knockout tissues or cells when available

• Isotype controls for flow cytometry and immunostaining

• Secondary antibody-only controls to assess non-specific binding

Validation controls:

• Peptide competition assays to confirm specificity

• siRNA/shRNA knockdown of MRC2 to verify signal reduction

• Use multiple antibodies recognizing different epitopes

How can I use MRC2 antibodies to study collagen uptake and degradation?

Studying collagen uptake using MRC2 antibodies requires specialized approaches:

Flow cytometry-based fluorescent collagen uptake assay:

• Isolate target cells (e.g., fibroblasts identified as CD45-PDGFRA+)

• Incubate cells with fluorescently labeled collagen

• Use MRC2 antibodies to correlate receptor expression with collagen uptake

• Include controls such as MRC2 knockout or blocking antibodies

• Analyze using flow cytometry to quantify internalized collagen

Tissue-based collagen degradation studies:

• Use DQ-collagen degradation assay to measure collagenolytic activity

• Combine with MRC2 immunostaining to correlate expression with activity

• Include appropriate controls such as collagenase treatment

• Quantify using arbitrary fluorescence units (AFU)

For in vivo studies, consider:

• Comparing MRC2 knockout models with wild-type animals

• Age-dependent analyses, as MRC2-mediated collagen turnover changes with maturation

• Correlating MRC2 expression levels (by Western blot or qRT-PCR) with collagen uptake capacity

What approaches can help troubleshoot inconsistent results with MRC2 antibodies?

When facing inconsistent results with MRC2 antibodies, consider these methodological approaches:

For weak or absent signal:

• Verify sample MRC2 expression levels using qRT-PCR

• Try multiple antibodies targeting different epitopes

• Optimize antibody concentration through titration experiments

• Modify antigen retrieval methods for fixed tissues

• Extend primary antibody incubation (e.g., overnight at 4°C)

For high background:

• Increase blocking duration (5% milk or BSA for 1+ hours)

• Optimize antibody dilution (test ranges from 1:500 to 1:8000 for WB)

• Use more stringent washing protocols (longer or additional wash steps)

• If using a polyclonal antibody, try a monoclonal alternative

• For immunostaining, include an IgG control at equal concentration

For contradictory results between methods:

• Consider that MRC2 behavior differs by cell/tissue type

• Age-dependent expression changes might explain discrepancies

• Verify antibody compatibility with your experimental conditions

• Use multiple complementary approaches (e.g., WB + IF + qPCR)

How can I design experiments to study MRC2's role in cancer progression and metastasis?

MRC2 has been implicated in cancer progression, particularly in sarcomas . To study this relationship:

Cell-based approaches:

• Compare MRC2 expression between normal and cancer cell lines using western blotting

• Manipulate MRC2 expression through overexpression or knockdown

• Assess functional outcomes including:

  • Cell migration and invasion assays

  • Collagen degradation capacity

  • Cell proliferation rates

Tissue-based approaches:

• Analyze MRC2 expression in tumor versus normal tissues

  • Use immunohistochemistry (IHC) for localization (3 μg/mL overnight at 4°C)

  • Quantify using qRT-PCR for mRNA levels

• Correlate expression with clinical outcomes and tumor characteristics

Animal models:

• Generate xenograft models using MRC2-expressing cancer cells

• Test MRC2-targeting antibodies for potential therapeutic effects

• Consider antibody-drug conjugate (ADC) approaches, as MRC2's rapid internalization makes it ideal for ADC delivery

• Monitor both primary tumor growth and metastatic spread

What are the considerations when developing an antibody-drug conjugate targeting MRC2?

MRC2's properties make it an attractive target for antibody-drug conjugate (ADC) development :

Key experimental design considerations:

• Antibody selection: Choose antibodies with:

  • High specificity and affinity for MRC2

  • Rapid internalization properties

  • Appropriate epitope targeting (e.g., mAb A5/158 targeting CTLD2)

• Linker-payload design:

  • Use cleavable linkers (e.g., vc-PAB) for lysosomal release

  • Select payloads with high potency (e.g., MMAE)

  • Optimize drug-to-antibody ratio (DAR) between 3-4 for balance of stability and efficacy

• Validation approaches:

  • Confirm rapid internalization using fluorescently labeled antibodies

  • Verify lysosomal trafficking using co-localization with LysoTracker

  • Assess target-dependent cytotoxicity against MRC2+ and MRC2- cell lines

  • Determine specificity using isotype-matched control ADCs

• In vivo testing:

  • Use xenograft models to evaluate tumor regression

  • Monitor metastatic colonization (lungs, liver, lymph nodes)

  • Include appropriate controls (unconjugated antibody, isotype-matched ADC)

This approach has shown promise in sarcoma models, demonstrating both primary tumor regression and reduced metastasis .

How do I optimize MRC2 antibody detection in challenging tissues or cell types?

When working with tissues or cells where MRC2 detection is challenging, consider these optimization strategies:

For fixed tissue sections:

• Antigen retrieval optimization:

  • Test different retrieval methods (heat-induced in citrate vs. EDTA buffers)

  • Optimize retrieval duration (10-30 minutes)

  • Consider enzymatic retrieval for some tissues

• Signal amplification:

  • Employ tyramide signal amplification (TSA) systems

  • Use biotin-streptavidin amplification methods

  • Consider polymer detection systems for IHC

• Antibody optimization:

  • Test a range of concentrations (1-10 μg/mL)

  • Extend incubation times (overnight at 4°C)

  • Try different antibody clones targeting distinct epitopes

For flow cytometry applications:

• Optimize cell preparation (enzymatic vs. mechanical dissociation)

• Include viability dyes to exclude dead cells

• Use fluorophores with appropriate brightness for your target population

• Consider cell surface vs. intracellular staining protocols

What are the important considerations for quantifying MRC2 expression across experimental models?

When quantifying MRC2 expression for comparative studies:

For protein-level analysis:

• Western blot quantification:

  • Use loading controls appropriate for your experimental conditions (e.g., GAPDH)

  • Employ densitometry with standard curves for semi-quantitative analysis

  • Normalize to total protein (using stain-free gels or Ponceau staining)

• Flow cytometry quantification:

  • Use calibration beads to convert mean fluorescence intensity to antibody binding capacity

  • Report data as fold-change over isotype control

  • Consider using standardized units like Molecules of Equivalent Soluble Fluorochrome (MESF)

For mRNA-level analysis:

• qRT-PCR considerations:

  • Normalize to stable housekeeping genes using the 2^-ΔΔCt method

  • Validate primer efficiency

  • Include technical and biological replicates

Cross-model standardization:

• Include common reference samples across experiments

• Report relative rather than absolute values when comparing across models

• Consider age-dependent expression differences in animal models

How can I distinguish between different MRC2 isoforms or related family members?

Distinguishing between MRC2 isoforms or related mannose receptor family members requires careful experimental design:

For isoform discrimination:

• Antibody selection:

  • Choose antibodies targeting regions specific to your isoform of interest

  • Review the immunogen information (e.g., which amino acid sequence was used)

• PCR-based approaches:

  • Design primers spanning exon junctions specific to each isoform

  • Use isoform-specific probes for qRT-PCR

  • Consider digital PCR for absolute quantification

• Western blot analysis:

  • Use high-resolution gels (e.g., 6% acrylamide) to separate close molecular weight isoforms

  • Look for characteristic molecular weight differences (isoform-specific patterns)

For family member distinction:

• Review cross-reactivity data in product documentation

• Include positive controls for each family member

• Consider using genetic approaches (siRNA, CRISPR) for validation

• Compare expression patterns across tissues known to differentially express family members

How can MRC2 antibodies be used to study age-dependent changes in collagen turnover?

Recent research has demonstrated age-dependent regulation of cell-mediated collagen turnover involving MRC2 . To study this phenomenon:

Experimental approaches:

• Age-comparative studies:

  • Compare MRC2 expression in tissues from young vs. mature animals

  • Use time-point series (e.g., PND, postnatal day; Wk, week; Mo, month)

  • Correlate expression with functional collagen uptake capacity

• Cell-specific analyses:

  • Sort cell populations (e.g., fibroblasts as CD45-PDGFRA+, myeloid cells as CD45+F4/80+)

  • Compare MRC2 expression and collagen uptake between populations

  • Use immunofluorescence co-staining to identify cell-specific expression patterns

• Mechanistic investigations:

  • Assess how MRC2 expression correlates with age-dependent phenotypes

  • Examine whether restoring MRC2 expression can rescue age-related defects

  • Study regulatory mechanisms controlling age-dependent MRC2 expression

This approach has revealed that fibroblasts, but not myeloid cells, show decreased MRC2-dependent collagen uptake with maturation, suggesting cell-specific roles in age-related matrix remodeling .

What are the emerging applications of MRC2 antibodies in cancer research and therapeutic development?

MRC2 antibodies are finding new applications in cancer research based on the receptor's roles in matrix remodeling and cell invasion:

Diagnostic applications:

• Tissue biomarker for cancer progression in sarcomas and other cancer types

• Potential prognostic indicator based on expression levels

• Marker for stromal activation in tumor microenvironments

Therapeutic applications:

• Antibody-drug conjugates (ADCs):

  • MRC2's rapid internalization makes it ideal for ADC approaches

  • Demonstrated efficacy in sarcoma models for both primary tumors and metastases

  • Potential for broad application across multiple sarcoma subtypes

• Blocking antibodies:

  • Potential to inhibit MRC2-mediated invasion and migration

  • May reduce collagen remodeling in the tumor microenvironment

  • Could complement existing cancer therapies

• Combination approaches:

  • Targeting MRC2 alongside matrix metalloproteinases

  • Combining with immune checkpoint inhibitors

  • Using in neoadjuvant settings to reduce invasion before surgery

These approaches are particularly promising given the lack of phenotype in MRC2 knockout mice, suggesting potentially reduced toxicity for MRC2-targeted therapies .